Biopharmaceutical Characterization of Grapiprant Within the BCS Framework Under Canine-Relevant Conditions: Solubility and Caco-2 Permeability Assessment
Zeyu Wen, Xilu Sun, Sumeng Chen, Jinyan Meng, Runlin Yu, Shuyan Guo, Xingyuan Cao · 2026
Read Biopharmaceutical Characterization of Grapiprant Within the BCS Framework Under Canine-Relevant Conditions: Solubility and Caco-2 Permeability Assessment by Zeyu Wen, Xilu Sun, Sumeng Chen, Jinyan Meng, Runlin Yu, Shuyan Guo, Xingyuan Cao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13516831.txt.
Description
Zeyu Wen and co-authors profile the pain drug grapiprant under dog-relevant conditions, in a 2026 paper. Grapiprant is an oral tablet that eases osteoarthritis pain and inflammation in dogs by blocking one prostaglandin receptor. The standard drug classification system sorts compounds by solubility and gut permeability, but it was built for human bodies, not canine ones.
The team measured how well the drug dissolves across acidity levels matching a dog's gut, and how it crosses a cultured cell layer that mimics the intestinal wall. Solubility barely shifted with acidity, while crossing stayed generally limited and varied with conditions. The profile helps vets and drug makers judge how the tablet behaves inside dogs.
Catalog record
| CREATOR | Zeyu Wen, Xilu Sun, Sumeng Chen, Jinyan Meng, Runlin Yu, Shuyan Guo, Xingyuan Cao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |